血浆EB病毒DNA用于地方性鼻咽癌疾病监测:真实世界数据库分析
该研究利用单中心真实世界数据库,纳入2017年2月至2023年7月接受根治性放疗的非转移性鼻咽癌患者,采用统一BamHI-W PCR法检测血浆EBV DNA,评估其复发监测的准确性。结果显示阴性预测值高(97.6%-99.3%),阳性预测值中等,且≥500 copies/mL阈值下窗口1的阳性预测值较高。
要点
- 阴性EBV DNA结果阴性预测值高(97.6%-99.3%),提示患者可常规监测。
- 阳性结果≥500 copies/mL提示高复发风险,窗口1阳性预测值26.3%-34.3%。
- 阳性预测值呈阈值依赖性,≥500 copies/mL者复发中位时间0.8个月。
核心结论
- 阴性EBV DNA检测结果具有高阴性预测值,提示患者可接受常规监测;阳性结果≥500 copies/mL提示高复发风险。
研究设计与样本
- 单中心真实世界数据库分析,纳入2017年2月至2023年7月治疗的393例组织学确诊、非转移性鼻咽癌患者,所有患者在放疗后3年内至少接受1次统一BamHI-W PCR法EBV DNA检测。
主要发现
- 1746次EBV DNA检测中,阴性1385次(79.3%),低值(<500 copies/mL)294次(16.8%),高值(≥500 copies/mL)67次(3.9%)。
- 阴性预测值范围为97.6%-99.3%。
- 阳性预测值在窗口1最高(范围26.3%-34.3%),其他3个窗口为2.6%-10.5%。
- 敏感性分析显示阳性预测值呈阈值依赖性:窗口1中≥500 copies/mL者为71.4%-100%,<500 copies/mL者为16.9%-23.1%,对应复发中位时间分别为0.8个月与4.8个月。
临床怎么用
- 阴性EBV DNA检测结果具有高阴性预测值,提示患者可接受常规监测;阳性结果≥500 copies/mL提示高复发风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Plasma Epstein-Barr virus (EBV) DNA is an archetypal biomarker for endemic nasopharyngeal carcinoma (NPC) employed for disease surveillance and early detection of recurrences. However, its accuracy is unknown. We utilised a single institution dataset with homogeneous surveillance procedures and routine EBV DNA testing using a harmonised assay to investigate its accuracy for recurrence detection. METHODS: We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised BamHI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals - windows 1-4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation. RESULTS: Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (< 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6-99.3 %). PPVs were modest, highest at window 1 (range: 26.3-34.3 %) compared with the other 3 windows (range: 2.6-10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4-100 % at window 1 for ≥ 500 copies/mL versus 16.9-23.1 % for < 500 copies/mL, which corresponded to median time of recurrence onset (0.8 vs 4.8 months, respectively). CONCLUSIONS: Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.
引用
- Neo J, Ong EHW, Zhang X, et al. Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database. Eur J Cancer. 2025. PMID: 40179820. doi:10.1016/j.ejca.2025.115396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。